This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer’s disease
Dubois, Bruno,
Zaim, Mohammed,
Touchon, Jacques,
Vellas, Bruno,
Robert, Philippe,
Murphy, Michael F.,
Pujadas-Navinés, Francesc,
Rainer, Michael,
Soininen, Hilkka,
Riordan, Henry J.,
Kanony-Truc, Claire
New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]
Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial
Newhouse, P.,
Kellar, K.,
Aisen, P.,
White, H.,
Wesnes, K.,
Coderre, E.,
Pfaff, A.,
Wilkins, H.,
Howard, D.,
Levin, E. D.
Objective: To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).; Methods: Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous […]
Cognitive stimulation in a-MCI: an experimental study
Moro, V.,
Condoleo, M. T.,
Sala, F.,
Pernigo, S.,
Moretto, G.,
Gambina, G.
Nowadays, preventing the effects of mental decline is an international priority, but there is little research into cognitive training in mild cognitive impairment (MCI). We present the results of a program aimed at teaching memory strategies and improving metacognitive abilities. This was associated with training to ameliorate caregivers’ assistance. Two groups (A and B) were […]
Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial
Boxer, Adam L.,
Appels, Bregje A.,
Kramer, Joel H.,
Merrilees, Jennifer,
Neuhaus, John,
Mesulam, M. Marsel,
Miller, Bruce L.
Background: Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD.; Methods: We did a randomised, parallel group, double-blind, placebo-controlled trial of […]
Effect of donepezil on emergence of apathy in mild to moderate Alzheimer’s disease
Waldemar, Gunhild,
Gauthier, Serge,
Jones, Roy,
Wilkinson, David,
Cummings, Jeffrey,
Lopez, Oscar,
Zhang, Richard,
Xu, Yikang,
Sun, Yijun,
Nakano, Seigo,
Richardson, Sharon,
Mackell, Joan
Objective: To determine whether donepezil treatment (10 mg/day over 24 weeks) is associated with delayed emergence of apathy in patients with mild to moderate Alzheimer’s disease (AD) and to explore relationships between donepezil’s effects on apathy and other Neuropsychiatric Inventory (NPI)-measured behavioural symptoms.; Methods: Two randomised, double-blind, parallel-group, placebo-controlled studies that met prespecified criteria and […]
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase 2 trial.; Methods: One-hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, […]
Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease
Mohamed, Somaia,
Rosenheck, Robert,
Lyketsos, Constantine G.,
Kaczynski, Richard,
Sultzer, David L.,
Schneider, Lon S.
Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]